


Affinia Therapeutics Email Formats
Biotechnology Research • Waltham, Massachusetts, United States • 21-50 Employees
Affinia Therapeutics Email Formats
Affinia Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@affiniatx.com), used 76.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@affiniatx.com | 76.5% |
{first name}{last name} | johndoe@affiniatx.com | 23.5% |
Key Contacts at Affinia Therapeutics
Darren Ottaviani
Executive Director, People Strategy & Operations
Michael Dibiasio-White
Head Of Process Development And Manufacturing Innovations-Associate Director
Michael Ma
Sr. Director, Program Management
Giri Murlidharan
Senior Director, Head Of Vector Translational Biology
Rob Aboud
Co-Founder And Chief Legal Officer
Yang Wang
Associate Director
John Reece-Hoyes
Senior Director, Head Of Vector Biology
Nicholas Robinson
Senior Director, Pathology
Julia Breslin Foster
Senior Director Legal Counsel
Jie Tan
Associate Director, Computational Science
Company overview
| Headquarters | 43 Foundry, Ste 120, Waltham, Massachusetts 02453, US |
| Phone number | +16174307817 |
| Website | |
| NAICS | 541714 |
| Keywords | Biotechnology, Research, Discovery, Teamwork, Integrity, AAV, Rare Diseases, Passion, Vector, Gene Therapy, Capsid |
| Founded | 2019 |
| Employees | 21-50 |
| Socials |
About Affinia Therapeutics
We are a team with decades of proven success in translating science from bench to bedside across many companies and medicines, in gene therapy and beyond. We are driven by a purpose: to make a lasting positive impact in the lives of people affected by devastating rare and prevalent diseases where the genetic cause is understood. Our thesis is simple and our vision, clear: gene therapies have an immense potential to cure many diseases with a one-time dose, but they are limited by current delivery methods for the genetic payload. We formed Affinia Therapeutics to singularly focus on creating innovations that can expand the reach of gene therapies to more prevalent diseases. We're re-engineering adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method that has shown promise but only in a small number of diseases. Our initial focus is on diseases of the heart and the nervous system, where we foresee a generational change in the treatment paradigm similar to what has happened in the treatment of cancers. This is because advances in science are identifying new genes associated with diseases of the heart and the nervous system, making a compelling case for genetic medicines. The heart and nervous system are also tissues where targeted delivery of the therapeutic genetic payload is currently inadequate. Our ART platform gives us an advantage to develop first-in-class or best-in-class product candidates. As an early team member you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun. Our site includes: State of the Art lab space & Equipment- Healthy Cafe, Outdoor Patio, State of the Art Gym/Yoga Studio, Lounge ( Pool Table/ Golf Simulator ), Free/Plentiful Parking and More! Join Us!
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Affinia Therapeutics has 28 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Affinia Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Affinia Therapeutics Tech Stack
Discover the technologies and tools that power Affinia Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Video players
UI frameworks
WordPress plugins
Miscellaneous
Form builders
JavaScript libraries
Security
Issue trackers
JavaScript frameworks
JavaScript libraries
JavaScript libraries
Frequently asked questions
4.8
40,000 users



